Crimean–Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a research and development roadmap for CCHF that prioritised the development and deployment of the medical countermeasures most needed by CCHF-affected countries. This Personal View presents updated CCHF research and development priorities and is the product of broad consultation with a working group of 20 leading experts in 2023–24. The strategic goals, milestones, and timelines have been revised and expanded to reflect scientific advances since 2019, including the identification of antibodies with therapeutic potential and the progression of four vaccine candidates through phase 1 clinical trials. This update emphasises the need for a One Health approach to manage CCHF, from integrated cross-sectoral surveillance to novel interventions that target ticks and their vertebrate hosts to reduce CCHF virus transmission to humans. The overarching vision for rapid diagnostics and specific therapeutics by 2028, followed by options to limit CCHF virus transmission and control disease by 2030, is deliberately ambitious and will only be achieved through coordinated international action from affected countries, funders, scientists, product developers, manufacturers, regulators, national authorities, and policy makers.

中文翻译：

---

克里米亚-刚果出血热的研究和产品开发：2024-30 年的优先事项


克里米亚-刚果出血热 （CCHF） 是一种分布广泛且可能致命的蜱传病毒性疾病，目前尚无获得许可的特异性治疗方法或疫苗。2019 年，世卫组织发布了 CCHF 研发路线图的先稿，该路线图优先开发和部署受 CCHF 影响的国家最需要的医疗对策。本个人观点介绍了 CCHF 最新的研发重点，是 2023-24 年与 20 名领先专家组成的工作组广泛协商的产物。自 2019 年以来，战略目标、里程碑和时间表已经过修订和扩展，以反映科学进步，包括确定具有治疗潜力的抗体以及四种候选疫苗通过 1 期临床试验的进展。此次更新强调了采用“同一个健康”方法来管理 CCHF 的必要性，从综合跨部门监测到针对蜱虫及其脊椎动物宿主的新型干预措施，以减少 CCHF 病毒向人类的传播。到 2028 年快速诊断和特定疗法的总体愿景，以及到 2030 年限制 CCHF 病毒传播和控制疾病的选择，是雄心勃勃的，只有通过受影响国家、资助者、科学家、产品开发商、制造商、监管机构、国家当局和政策制定者采取协调一致的国际行动才能实现。